Jiangsu Hengrui Pharmaceuticals (01276): HRS-5346 Tablets Approved to Initiate Clinical Trials

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiary Shandong Shengdi Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for HRS-5346 tablets, and will initiate clinical trials in the near future. HRS-5346 is an oral small-molecule inhibitor of Lp(a), demonstrating the potential to prevent the risk of atherosclerotic cardiovascular disease by effectively lowering Lp(a), and oral administration is also expected to provide greater convenience for patients. Upon review, no similar drugs have been approved for marketing domestically or internationally to date. As of now, the cumulative R&D investment in HRS-5346 tablet-related projects is approximately RMB86.2 million (unaudited).